Amneal Pharmaceuticals Reports Q2 2026 Earnings with Revenue Growth and Raised Guidance
Amneal Pharmaceuticals (AMRX) reported second-quarter revenue of $796 million, a 10% year-over-year increase driven by strong performance across all three business segments. Adjusted EBITDA rose to $206 million (+12%), while adjusted EPS reached $0.30 (+20%) due to higher profitability and lower interest expenses. The Affordable Medicines segment saw a 13% revenue growth, led by complex generics and injectables. The Specialty segment grew 17%, driven by products like CREXONT and UNITHROID. AvKARE's revenue declined slightly (-4%), impacted by the low-margin distribution business despite government channel gains. Amneal raised its full-year guidance for revenue to $3.1 billion–$3.2 billion, adjusted EBITDA to $750 million–$780 million, and adjusted EPS to $0.96–$1.06. The company also announced a capital expenditure increase of $40 million to support U.S. injectable expansion and Women's Health demand.
Tickers: $AMRX
Topics: adjusted_ebitda adjusted_eps guidance_update revenue segment_performance